Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
This is an open-label, multicenter, ascending multiple dose study of REGN1400 alone and in combination with erlotinib or cetuximab administered to patients with certain types of cancer.
Cancer
DRUG: REGN1400|DRUG: Erlotinib|DRUG: Cetuximab
The primary objective of the study is to characterize the safety profile of REGN1400 alone and in combination with erlotinib or cetuximab, Safety will be assessed through analysis of laboratory data, physical examination findings and vital signs according to the schedule of assessments, in addition to the spontaneous reporting of adverse events according to CTCAE version 4., Day 1 - Day 28
Recommended Phase 2 Dose (RP2D), Determine a recommended phase 2 dose (RP2D) of REGN1400 in combination with erlotinib or cetuximab, Day 1 to Day 28
This is an open-label, multicenter, ascending multiple dose study of REGN1400 alone and in combination with erlotinib or cetuximab administered to patients with certain types of cancer.